Drug-Eluting Stents. Is Their Future as Bright as Their Past?**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 50, Issue 2, 2007, Pages 146-148

  Kastrati, Adnan ^a   Schömig, Albert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; RAPAMYCIN; TICLOPIDINE; TIROFIBAN;

CARDIOLOGY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORONARY STENT; DRUG ELUTING STENT; EDITORIAL; HEART INFARCTION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; RISK ASSESSMENT; SAFETY; THROMBOSIS;

CORONARY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG DELIVERY SYSTEMS; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSTHESIS DESIGN; STENTS;

EID: 34347270167     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.04.028     Document Type: Editorial

References (12)

1. Schömig A., Kastrati A., and Wessely R. Prevention of restenosis by systemic drug therapy: back to the future?. Circulation 112 (2005) 2759-2761
2. Valgimigli M., Percoco G., Malagutti P., et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 293 (2005) 2109-2117
3. Moliterno D.J., Yakubov S.J., DiBattiste P.M., et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet 360 (2002) 355-360
4. Spaulding C., Henry P., Teiger E., et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 55 (2006) 1093-1104
5. Valgimigli M., Campo G., Arcozzi C., et al. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa inhibitor infusion in patients with myocardial infarction: results from the STRATEGY study. J Am Coll Cardiol 50 (2007) 138-145
6. Curfman G.D., Morrissey S., Jarcho J.A., and Drazen J.M. Drug-eluting coronary stents-promise and uncertainty. N Engl J Med 350 (2007) 1059-1060
7. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
8. Camenzind E. Safety of Drug-Eluting Stents: Insights From Meta Analysis. Available at: http://www.escardio.org/knowledge/congresses/CongressReports/hotlinesand ctus/707009_Camenzind.htm. Accessed February 16, 2007.
9. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
10. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
11. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
12. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 49 (2007) 734-739